GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Odonate Inc (OTCPK:ODTC) » Definitions » COGS-to-Revenue

Odonate (Odonate) COGS-to-Revenue : 0.00 (As of Sep. 2021)


View and export this data going back to 2017. Start your Free Trial

What is Odonate COGS-to-Revenue?

Odonate's Cost of Goods Sold for the three months ended in Sep. 2021 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2021 was $0.00 Mil.

Odonate's COGS to Revenue for the three months ended in Sep. 2021 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Odonate's Gross Margin % for the three months ended in Sep. 2021 was N/A%.


Odonate COGS-to-Revenue Historical Data

The historical data trend for Odonate's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Odonate COGS-to-Revenue Chart

Odonate Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
COGS-to-Revenue
Get a 7-Day Free Trial - - - - -

Odonate Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Odonate COGS-to-Revenue Calculation

Odonate's COGS to Revenue for the fiscal year that ended in Dec. 2020 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Odonate's COGS to Revenue for the quarter that ended in Sep. 2021 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Odonate  (OTCPK:ODTC) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Odonate's Gross Margin % for the three months ended in Sep. 2021 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Odonate COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Odonate's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Odonate (Odonate) Business Description

Traded in Other Exchanges
N/A
Address
3 East 28th Street, 10th Floor, New York, NY, USA, 10016
Odonate Inc is a Shell company.
Executives
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Boxer Capital, Llc director, 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Kevin C Tang director, 10 percent owner, officer: Chief Executive Officer 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Aaron I. Davis director, 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Jeff L Vacirca director 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Laura L. Johnson director C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Michael S Hearne officer: Chief Financial Officer 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Joseph P O'connell officer: Chief Medical Officer 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Boxer Asset Management Inc. 10 percent owner CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Robert Rosen director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Joseph Lewis 10 percent owner PO BOX N7776, LYFORD BAHAMAS
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
John G Lemkey officer: Chief Financial Officer 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121

Odonate (Odonate) Headlines

From GuruFocus

Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Sold $5.7 million of Shares

By GuruFocus Research GuruFocus Editor 11-20-2021